Immunotherapy is the new black when it comes to treating Cancer, raising hope in conquering this age old illness.
Biovest Seeking Marketing Approval in the EU for BiovaxID® Personalized Lymphoma Cancer Vaccine
Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed.
Biovest CEO and Sr. Vice President Discuss Global Marketing of BiovaxID
Biovest International, Inc. (OTCQB: BVTI) announced that Biovest is seeking marketing approval in Canada for BiovaxID®, its personalized cancer vaccine for the treatment of follicular non-Hodgkin’s lymphoma.